Literature DB >> 25641766

Capillary zone electrophoresis on-line coupled to mass spectrometry: A perspective application for clinical proteomics.

Martin Pejchinovski1, Dajana Hrnjez1, Adela Ramirez-Torres1, Vasiliki Bitsika2, George Mermelekas2, Antonia Vlahou2,3, Petra Zürbig1, Harald Mischak1,4, Jochen Metzger1, Thomas Koeck1.   

Abstract

Clinical proteomics, a rapidly growing field, intends to use specific diagnostic proteomic/peptidomic markers for initial diagnosis or prognosis of the progression of various diseases. Analyses of disease-associated markers in defined biological samples can provide valuable molecular diagnostic information for these diseases. This approach relies on sensitive and highly standardized modern analytical techniques. In the recent years, one of these technologies, CZE online coupled to MS (CZE-MS), has been increasingly used for the detection of peptide biomarkers (<20 kDa) in body fluids such as urine. This review presents the most relevant urinary proteomic studies addressing the application of CZE-MS in clinically relevant biomarker research between the years 2006 and 2014.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Keywords:  Biomarker; Capillary electrophoresis-mass spectrometry; Clinical; Proteomics

Mesh:

Substances:

Year:  2015        PMID: 25641766     DOI: 10.1002/prca.201400113

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  8 in total

Review 1.  Urinary biomarkers for renal tract malformations.

Authors:  Pedro Magalhães; Joost P Schanstra; Emma Carrick; Harald Mischak; Petra Zürbig
Journal:  Expert Rev Proteomics       Date:  2016-11-15       Impact factor: 3.940

Review 2.  Urinary proteomics using capillary electrophoresis coupled to mass spectrometry for diagnosis and prognosis in kidney diseases.

Authors:  Pedro Magalhães; Harald Mischak; Petra Zürbig
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-11       Impact factor: 2.894

Review 3.  Biomarker discovery in mass spectrometry-based urinary proteomics.

Authors:  Samuel Thomas; Ling Hao; William A Ricke; Lingjun Li
Journal:  Proteomics Clin Appl       Date:  2016-02-11       Impact factor: 3.494

4.  Acute kidney injury prediction in cardiac surgery patients by a urinary peptide pattern: a case-control validation study.

Authors:  Jochen Metzger; William Mullen; Holger Husi; Angelique Stalmach; Stefan Herget-Rosenthal; Heiner V Groesdonk; Harald Mischak; Matthias Klingele
Journal:  Crit Care       Date:  2016-05-26       Impact factor: 9.097

5.  Urinary Proteomics Pilot Study for Biomarker Discovery and Diagnosis in Heart Failure with Reduced Ejection Fraction.

Authors:  Kasper Rossing; Helle Skovmand Bosselmann; Finn Gustafsson; Zhen-Yu Zhang; Yu-Mei Gu; Tatiana Kuznetsova; Esther Nkuipou-Kenfack; Harald Mischak; Jan A Staessen; Thomas Koeck; Morten Schou
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240

6.  Identification of ageing-associated naturally occurring peptides in human urine.

Authors:  Esther Nkuipou-Kenfack; Akshay Bhat; Julie Klein; Vera Jankowski; William Mullen; Antonia Vlahou; Mohammed Dakna; Thomas Koeck; Joost P Schanstra; Petra Zürbig; Karl L Rudolph; Björn Schumacher; Andreas Pich; Harald Mischak
Journal:  Oncotarget       Date:  2015-10-27

7.  Prediction of acute coronary syndromes by urinary proteome analysis.

Authors:  Nay M Htun; Dianna J Magliano; Zhen-Yu Zhang; Jasmine Lyons; Thibault Petit; Esther Nkuipou-Kenfack; Adela Ramirez-Torres; Constantin von Zur Muhlen; David Maahs; Joost P Schanstra; Claudia Pontillo; Martin Pejchinovski; Janet K Snell-Bergeon; Christian Delles; Harald Mischak; Jan A Staessen; Jonathan E Shaw; Thomas Koeck; Karlheinz Peter
Journal:  PLoS One       Date:  2017-03-08       Impact factor: 3.240

Review 8.  CE-MS for metabolomics: Developments and applications in the period 2014-2016.

Authors:  Rawi Ramautar; Govert W Somsen; Gerhardus J de Jong
Journal:  Electrophoresis       Date:  2016-10-31       Impact factor: 3.535

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.